NASDAQ:OPTN OptiNose (OPTN) Stock Price, News & Analysis → Wall Street legend who predicted 2021 tech crash issues new warning (From Chaikin Analytics) (Ad) Free OPTN Stock Alerts $1.18 +0.06 (+5.33%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$1.11▼$1.1950-Day Range$0.82▼$1.9452-Week Range$0.80▼$2.10Volume568,954 shsAverage Volume887,269 shsMarket Capitalization$133.95 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get OptiNose alerts: Email Address OptiNose MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside209.4% Upside$3.67 Price TargetShort InterestBearish5.24% of Shares Sold ShortDividend StrengthN/ASustainability-2.10Upright™ Environmental ScoreNews Sentiment0.25Based on 20 Articles This WeekInsider TradingSelling Shares$68,812 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.26) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.93 out of 5 starsMedical Sector229th out of 928 stocksPharmaceutical Preparations Industry95th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingOptiNose has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOptiNose has only been the subject of 2 research reports in the past 90 days.Read more about OptiNose's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.24% of the outstanding shares of OptiNose have been sold short.Short Interest Ratio / Days to CoverOptiNose has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in OptiNose has recently increased by 84.42%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOptiNose does not currently pay a dividend.Dividend GrowthOptiNose does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOptiNose has received a 60.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sumatriptan", "Nasal medication (R01)", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for OptiNose is -2.10. Previous Next 2.4 News and Social Media Coverage News SentimentOptiNose has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for OptiNose this week, compared to 1 article on an average week.Search Interest2 people have searched for OPTN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added OptiNose to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptiNose insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $68,812.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of OptiNose is held by insiders.Percentage Held by Institutions85.60% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptiNose's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptiNose are expected to grow in the coming year, from ($0.26) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptiNose is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptiNose is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about OptiNose's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Manward PressThis unknown company solves the biggest issue with AINvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company About OptiNose Stock (NASDAQ:OPTN)OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Read More OPTN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPTN Stock News HeadlinesMay 15 at 10:03 PM | markets.businessinsider.comOptinose’s XHANCE Expansion Drives Buy Rating Amidst Growth PotentialMay 15 at 10:03 PM | msn.comOptinose Reports Growth in Q1 and Optimistic Outlook for XHANCEMay 15 at 4:54 AM | finance.yahoo.comOptiNose Inc (OPTN) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...May 14 at 12:07 PM | investorplace.comOPTN Stock Earnings: OptiNose Misses EPS, Beats Revenue for Q1 2024May 14 at 9:03 AM | finance.yahoo.comOptinose Reports First Quarter 2024 Financial Results and Recent Operational HighlightsMay 14 at 7:00 AM | globenewswire.comOptinose Reports First Quarter 2024 Financial Results and Recent Operational HighlightsMay 13 at 11:02 PM | ca.finance.yahoo.comOptiNose, Inc. (OPTN) Stock Price, News, Quote & History - Yahoo FinanceMay 12 at 6:48 AM | msn.comOptinose to Unveil First Quarter 2024 Financial Results and UpdatesMay 12 at 3:20 AM | americanbankingnews.comOptiNose (OPTN) Scheduled to Post Earnings on TuesdayMay 10, 2024 | finance.yahoo.comOptiNose Inc (OPTN) Announces $55 Million Financing Round Amidst Revenue ProjectionsMay 10, 2024 | globenewswire.comOptinose Announces Reporting Date for First Quarter 2024 Financial ResultsMay 9, 2024 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on Optinose (OPTN)May 9, 2024 | finance.yahoo.comOptinose Announces $55 Million Registered Direct OfferingMay 5, 2024 | finance.yahoo.comRecent uptick might appease OptiNose, Inc. (NASDAQ:OPTN) institutional owners after losing 50% over the past yearApril 29, 2024 | bizjournals.comAfter key Xhance approval, Optinose outlines plan to quadruple sales and reach profitabilityApril 27, 2024 | finance.yahoo.comOptiNose, Inc. (OPTN)April 25, 2024 | investorplace.comWhy Is OptiNose (OPTN) Stock Up 12% Today?April 25, 2024 | globenewswire.comOptinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 millionApril 7, 2024 | msn.comOptinose to Present at Needham Virtual Healthcare ConferenceApril 6, 2024 | finance.yahoo.comOptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years agoApril 4, 2024 | globenewswire.comOptinose to Present at the Needham Virtual Healthcare ConferenceMarch 16, 2024 | finanznachrichten.deOptinose, Inc.: XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsMarch 16, 2024 | msn.comOptiNose granted FDA nod to expand labeling for sinusitis therapyMarch 15, 2024 | bizjournals.comBucks County's Optinose wins FDA approval for wider use of flagship productMarch 15, 2024 | globenewswire.comXHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsSee More Headlines Receive OPTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/15/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OPTN CUSIPN/A CIK1494650 Webwww.optinose.com Phone(267) 364-3500FaxN/AEmployees132Year FoundedN/APrice Target and Rating Average Stock Price Target$3.67 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+237.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,480,000.00 Net Margins-50.06% Pretax Margin-49.99% Return on EquityN/A Return on Assets-33.05% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.55 Sales & Book Value Annual Sales$70.99 million Price / Sales1.89 Cash FlowN/A Price / Cash FlowN/A Book Value($0.77) per share Price / Book-1.54Miscellaneous Outstanding Shares113,040,000Free Float110,552,000Market Cap$133.95 million OptionableNot Optionable Beta-0.10 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Ramy A. Mahmoud M.D. (Age 59)M.P.H., CEO & Director Comp: $731.59kMr. Michael F. Marino Esq. (Age 48)Chief Legal Officer & Corporate Secretary Comp: $604.24kMr. Anthony J. Krick (Age 43)Vice President & Chief Accounting Officer Mr. Jonathan NeelyVice President of Investor Relations & Business OperationsMs. Karen E. Brophy (Age 61)Chief Human Resources Officer & VP of Human Resources Mr. Paul Spence (Age 56)Chief Commercial Officer More ExecutivesKey CompetitorsContext TherapeuticsNASDAQ:CNTXAmylyx PharmaceuticalsNASDAQ:AMLXKaryopharm TherapeuticsNASDAQ:KPTIPDS BiotechnologyNASDAQ:PDSBNuvectis PharmaNASDAQ:NVCTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 62,906 shares on 5/10/2024Ownership: 3.753%Easterly Investment Partners LLCBought 516,730 shares on 5/3/2024Ownership: 1.803%HighMark Wealth Management LLCBought 25,000 shares on 4/29/2024Ownership: 0.022%Rosalind Advisors Inc.Sold 344,091 shares on 4/25/2024Ownership: 4.032%Assenagon Asset Management S.A.Bought 50,662 shares on 4/24/2024Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions OPTN Stock Analysis - Frequently Asked Questions Should I buy or sell OptiNose stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPTN shares. View OPTN analyst ratings or view top-rated stocks. What is OptiNose's stock price target for 2024? 3 brokerages have issued twelve-month target prices for OptiNose's stock. Their OPTN share price targets range from $3.00 to $5.00. On average, they anticipate the company's stock price to reach $3.67 in the next year. This suggests a possible upside of 209.4% from the stock's current price. View analysts price targets for OPTN or view top-rated stocks among Wall Street analysts. How have OPTN shares performed in 2024? OptiNose's stock was trading at $1.29 at the beginning of 2024. Since then, OPTN stock has decreased by 8.1% and is now trading at $1.1850. View the best growth stocks for 2024 here. When is OptiNose's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our OPTN earnings forecast. How were OptiNose's earnings last quarter? OptiNose, Inc. (NASDAQ:OPTN) posted its earnings results on Thursday, March, 7th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. The firm had revenue of $19.87 million for the quarter, compared to analyst estimates of $19.90 million. During the same period in the prior year, the company posted ($0.17) earnings per share. What guidance has OptiNose issued on next quarter's earnings? OptiNose issued an update on its FY 2024 earnings guidance on Tuesday, May, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $85.0 million-$95.0 million, compared to the consensus revenue estimate of $90.5 million. What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX). When did OptiNose IPO? OptiNose (OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO. Who are OptiNose's major shareholders? OptiNose's stock is owned by a variety of institutional and retail investors. Top institutional investors include Rosalind Advisors Inc. (4.03%), Vanguard Group Inc. (3.75%), Easterly Investment Partners LLC (1.80%), Rice Hall James & Associates LLC (0.88%), Assenagon Asset Management S.A. (0.08%) and HighMark Wealth Management LLC (0.02%). Insiders that own company stock include Anthony J Krick, Keith A Goldan, Michael F Marino III, Michael F Marino III, Michele Janis, Peter K Miller, Ramy A Mahmoud, Ramy A Mahmoud and Victor M Clavelli. View institutional ownership trends. How do I buy shares of OptiNose? Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPTN) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsGold Set to EXPLODE!Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
